A defect of amphiregulin release predicted longer survival independently of <scp>YAP</scp> expression in patients with pleural mesothelioma in the <scp>IFCT</scp> ‐0701 <scp>MAPS</scp> phase 3 trial-Reference-Cited by-同舟云学术

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT ‐0701 MAPS phase 3 trial

Published:2022-03-16 Issue:11 Volume:150 Page:1889-1904
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Maille Elodie¹,Levallet Jérôme¹,Dubois Fatéméh¹²,Antoine Martine³,Danel Claire⁴,Creveuil Christian¹⁵,Mazieres Julien⁶,Margery Jacques⁷,Greillier Laurent⁸,Gounant Valérie⁹¹⁰,Moro‐Sibilot Denis¹¹,Molinier Olivier¹²,Léna Hervé¹³,Monnet Isabelle¹⁴,Bergot Emmanuel¹¹⁵,Langlais Alexandra¹⁶,Morin Franck¹⁶,Scherpereel Arnaud¹⁷,Zalcman Gérard¹⁰¹⁸,Levallet Guénaëlle¹²^ORCID

Affiliation:

1. Normandie Univ, UNICAEN, CNRS, ISTCT‐UMR6030 Caen GIP CYCERON France

2. Department of Pathology CHU de Caen Caen France

3. Department of Pathology Hôpital Tenon, AP‐HP Paris France

4. Department of Pathology Hôpital Bichat‐Claude Bernard, AP‐HP, Université Paris‐Diderot Paris France

5. Biomedical Research Unit CHU de Caen Caen France

6. Department of Pulmonology Hôpital Larrey, CHU de Toulouse Toulouse France

7. Department of Medical Oncology Institut Gustave Roussy Villejuif France

8. Department of Multidisciplinary Oncology and Therapeutic Innovations Assistance Publique Hôpitaux de Marseille, Université Aix‐Marseille UM015 Marseille France

9. Department of Pulmonology Hôpital Tenon, AP‐HP Paris France

10. Department of Thoracic Oncology & CIC 1425 University Hospital Bichat‐Claude Bernard, AP‐HP, Université de Paris Paris France

11. Pôle Thorax et Vaisseaux, University Hospital of Grenoble‐Alpes La Tronche France

12. Department of Pulmonology Centre Hospitalier Le Mans Le Mans France

13. Department of Pulmonology University Hospital Pontchaillou Rennes France

14. Department of Pulmonology Centre Hospitalier Intercommunal de Créteil Créteil France

15. Department of Pulmonology and Thoracic Oncology University Hospital of Caen Caen France

16. Intergroupe Francophone de Cancérologie Thoracique (IFCT) Paris France

17. Department of Pulmonary and Thoracic Oncology Centre Hospitalier Universitaire Lille, University of Lille, U1019 INSERM, Center of Infection and Immunity of Lille Lille France

18. U830 INSERM, “Cancer, Hétérogénéité, Instabilité et Plasticité” Centre de Recherche, Institut Curie Paris France

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33997

Reference51 articles.

1. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

2. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma

3. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

4. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province;Wagner JC;Br J Ind Med,1960

5. The role of hippo pathway in cancer stem cell biology;Park JH;Mol Cells,2018